Table 1 Patient characteristics and clinical outcome (nā=ā313)
Clinical, epidemiological, pathological, and surgical features | Value |
|---|---|
Mean ageāĀ±āSD, years | 66.5āĀ±ā7.3 |
Male sex, n (%) | 272 (87) |
Performance status, n (%) | |
ā0 | 222 (71) |
ā1 | 88 (28) |
ā2 | 3 (1) |
Tumor location, n (%) | |
āCe | 1 (0.3) |
āUt | 42 (13) |
āMt | 144 (46) |
āLt | 98 (31) |
āAe | 28 (9) |
Histopathological type, n (%) | |
āSquamous cell carcinoma | 279 (89) |
āAdenocarcinoma | 20 (6) |
āOthers | 14 (4) |
Pretreatment clinical stage, n (%) | |
āIB | 7 (2) |
āII | 53 (17) |
āIII | 218 (70) |
āIV | 35 (11) |
NAC regimen, n (%) | |
āPlatinum-based | 203 (65) |
āTaxane-based | 110 (35) |
RECIST (longest diameter), n (%) | |
āPR | 126 (40) |
āSD | 174 (56) |
āPD | 13 (4) |
RECIST (shorter axis), n (%) | |
āPR | 145 (46) |
āSD | 150 (48) |
āPD | 18 (6) |
Severe morbidity, n (%) | |
āCDCāā„āIIIb | 34 (11) |
Pathological stage, n (%) | |
ā0āI | 60 (19) |
āII | 88 (28) |
āIII | 158 (41) |
āIV | 37 (12) |
TRG | |
ā0 | 16 (5) |
ā1a | 184 (59) |
ā1b | 49 (16) |
ā2 | 45 (14) |
ā3 | 19 (6) |